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Abstract A number of previously unidentified 1H NMR signals
detected in CSF spectra of patients with various neurological and
metabolic diseases are assigned to metabolites, drugs and drug
excipients. Two-dimensional 1H NMR spectroscopy (COSY and
J-resolved) is employed to resolve resonances which are hidden
by superimposed peaks in one-dimensional spectra. Assignments
obtained by making use of 2-D techniques, and of a 1-D 1H
NMR data base created for ca. 150 authentic compounds, enable
us to clarify the nature of complex signal patterns found in
crowded spectral regions of CSF such as the aliphatic methyl
region at ca. 1.0 ppm.
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1. Introduction
One-dimensional 1H NMR spectroscopy has been used for
more than a decade to quantitatively analyze bio£uids such as
blood serum, plasma, cerebrospinal £uid (CSF), urine, amni-
otic £uid, etc. [1^12]. Determination of metabolite concentra-
tions in CSF is of particular interest for the diagnosis of
neurological diseases [1,6,13]. Moreover, correct NMR signal
assignment is a prerequisite for establishing hypotheses on the
nature of metabolic perturbations underlying the diseased
state. For these reasons, considerable e¡orts have been
made to assign the large number of resonances characterizing
high-resolution spectra of CSF and other bio£uids. Neverthe-
less, for many signals detected in CSF samples, assignments
have not been available. In a recent publication, we reported
signi¢cantly changed intensities of unassigned signals for mul-
tiple sclerosis vs. control patients [12]. We are now able to
present assignments for most of these signals. Additional res-
onances occasionally detected in our CSF spectra were as-
signed to drugs or drug excipients.
A great variety of methods and strategies exist for 1H NMR
signal assignment, ranging from the simple use of data pub-
lished in the literature to the application of rather sophisti-
cated pulse sequences for two-dimensional NMR spectros-
copy. While some 2-D NMR methods may not be
applicable to samples as diluted as CSF, assignments exclu-
sively relying on published chemical shift values may prove to
be erroneous due to inconsistent experimental conditions, no-
tably pH. We combined several experimental methods and
sources of information including (1) literature values for
chemical shifts and coupling constants as a preliminary ori-
entation, (2) use of a 1-D 1H NMR data base consisting of
400 MHz spectra for D2O solutions of ca. 150 authentic com-
pounds (pH 7.0), most of which were metabolites likely to be
found in CSF, (3) spiking CSF samples with authentic com-
pounds, (4) e¡ects of pH variation on 1-D 1H NMR spectra,
(5) selective homonuclear decoupling of 1-D 1H NMR spec-
tra, (6) homonuclear 2-D 1H NMR spectra (COSY, JRES) of
concentrated CSF samples, and (7) con¢rmation of NMR
assignments by an independent method (HPLC).
Metabolite quantitation is often compromised by signi¢cant
superposition of NMR signals. For this reason the spectral
region between 3.4 and 3.9 ppm (glucose) is rarely exploited in
CSF analysis. In contrast, a number of methyl resonances
lying in the ‘crowded’ region between 0.85 and 1.05 ppm
have been used for quantitative evaluation based on arbitrary
concentration units [12]. We investigated this latter region in
more detail by using homonuclear 2-D 1H NMR techniques
in order to interpret the spectroscopic pattern obtained by
1-D 1H NMR spectroscopy at 400 MHz for CSF samples at
pH 7.0.
2. Materials and methods
2.1. 1H NMR methods
CSF samples were collected by lumbar puncture, lyophilized and
prepared for NMR spectroscopy as described previously [12]. 1H
NMR spectroscopy for signal assignment was performed by using
concentrated CSF samples. Samples from several patients were pooled
to reach a concentration factor of v10. For one sample, 1H NMR
spectra were taken at varying pH values ranging from 2.5 to 7.0, in
intervals of ca. 0.5 pH units. Aqueous (D2O) model solutions con-
taining authentic compounds were prepared and adjusted to pH 7.0.
1H NMR spectra at 400.1 MHz were obtained on a 9.4 T Bruker AM-
400 FT-NMR spectrometer using a quattro nucleus probe for 5 mm
tubes. Small amounts of sodium 2,2P,3,3P-tetradeutero-3-trimethylsi-
lylpropionate (TSP) were added to the samples to provide chemical
shift reference. A standard Bruker BVT-1000 variable temperature
unit (VTU) was used to regulate the temperature of the air stream,
maintaining a sample temperature of 20‡C.
One-dimensional 1H NMR spectra were usually acquired using near
full relaxation conditions, i.e. a pulse repetition time (TR) of 13 s, a
pulse width (PW) of 14 Ws (90‡) and an acquisition time (AQ) of 1.36 s
(16 k data points), preceded by continuous wave (CW) water proton
presaturation for 4.6 s (power setting 14L, ca. 0.035 W). FIDs were
multiplied by an exponential function (LB = 0.2 Hz). After zero-¢lling,
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Fourier transform, phase and baseline corrections, peak maxima were
determined using Bruker’s DISNMR peak picking routine based on a
polynomial ¢t procedure.
For selective homonuclear irradiation, Bruker’s DISNMR micro-
program PRESATHD.AU was employed. Decoupler power was set
to 16L = ca. 0.02 W for both water suppression and selective irradi-
ation during acquisition. TR was 7.36 s, including a water suppression
period of 6 s before an rf pulse of PW (82‡) = 12.8 Ws. AQ was 1.36 s
(16 k data points).
Two-dimensional 1H NMR experiments were performed by using
standard pulse sequences for J-resolved, COSY-90 and COSY-45
spectroscopy. The number of t1 increments varied between 128 and
512 for COSY experiments. Most COSY spectra were obtained using
TD = 512 W in t1 (1 k in t2), zero-¢lled to 1 k (2 k), resulting in a
digital resolution of 3.9 Hz/point in both f1 and f2 (SW = 4 kHz;
512 t1 increments). J-resolved 2-D spectra were obtained using
TD = 8 k (128 W) for t2 (t1), zero-¢lled to 16 k (256 W), correspond-
ing to a digital resolution of 0.49 Hz/point (0.24 Hz/point). SW was
4 kHz in f2 (31.3 Hz in f1 with 128 t1 increments). Relaxation delay
RD was 3 s for all 2-D spectra (including CW water proton presatu-
ration). Two-dimensional spectra were treated with a sinebell window
¢lter function, and were symmetrized after 2-D FT. Spectra were
plotted at various intensity levels for analysis, and were evaluated
as described elsewhere [14]. Some correlation peaks of weakly con-
centrated metabolites could not be identi¢ed unambiguously due to
overlap with large correlation signals from highly concentrated com-
pounds (e.g. glutamine, glucose, citrate), or with t1 noise originating
from these compounds. However, correlation peaks for all coupled
methyl resonances assigned in this work were detected without di⁄-
culty.
2.2. Spectrum simulation
The spectral region between 0.82 and 1.08 ppm was simulated using
EXCEL 4.0 (Microsoft, Redmond, WA) to predict and visualize sig-
nal overlap for di¡erent magnetic ¢eld strengths B0 between 9.4 and
18.8 T. This limited objective allowed us to choose a simpli¢ed sim-
ulation algorithm. We assumed Lorentzian line shapes and identical
line widths for all signals of this spectral region. Chemical shifts and
coupling constants were taken from experimental spectra acquired at
400 MHz for reference solutions and CSF samples. Noise was ob-
tained from a signal free region (0.3^0.7 ppm) of an experimental 400
MHz CSF spectrum, and was added to the calculated spectrum. Dig-
ital resolution was kept constant at 0.33 Hz/point for all simulated
spectra, a value very close to that of our experimental spectra (0.37
Hz/point). Line widths, peak heights and noise levels were chosen as
to generate a simulated 400 MHz spectrum that acceptably matched
the experimental spectrum of a typical concentrated CSF sample.
Peak heights for the K-aminobutyrate methyl triplet were estimated
based on the skyline f2 projection of a JRES spectrum since this
triplet was entirely hidden in the experimental 1-D NMR spectrum.
We assumed that all multiplets of the spectral region in question
represent pure AX spin systems, resulting in ¢rst-order spectral pat-
terns with relative signal intensities (within a multiplet) given by the
binomial coe⁄cients of the Pascal triangle. This rule describes the
relevant methyl signals in good approximation since the relative chem-
ical shift, X0N, of each methyl multiplet, i.e. its distance from the
multiplet representing the coupled proton(s), is very large compared
with the coupling constant, J (X0N/Js 10) [15]. Consequently, errors
for coupling constants and signal intensities do not exceed 5% and
10%, respectively, for magnetic ¢eld strengths B0v 9.4 T. The noise
level was varied as a function of B0 to ensure that the signal-to-noise
ratio, S/N, was proportional to B03=2 [15].
2.3. HPLC
For HPLC analysis, 100 Wl CSF aliquots were deproteinized at 4‡C
by ultra¢ltration (Ultrafree-MC UFC3LGC-00 Millipore ¢lters for
small volumes). Amino acids were derivatized with phenylisothiocya-
nate, whereas oxoacids were analyzed without derivatization. HPLC
analyses were carried out using a Merck Hitachi system (Tokyo, Ja-
pan) equipped with an HPLC pump (model L 6200 A) and a variable-
wavelength detector (Model LaChrom L7400). For K-aminobutyrate
analysis a reversed-phase column was used [16], while K-oxoisovaler-
ate was examined using a cation-exchange Aminex HPX 87A column
(Bio-Rad, Richmond, CA, USA) [17]. All assays were run in dupli-
cate.
3. Results and discussion
3.1. Assignment of aliphatic methyl signals
3.1.1. The leucine/isoleucine region. The spectral range de-
¢ned by the chemical shift values 0.946 NH6 0.97 ppm is
commonly termed ‘Leu/Ile’ (leucine/isoleucine) in the biomed-
ical NMR literature [3,18^20]. The resolution usually achieved
for bio£uid or tissue extract 1H NMR spectra does not permit
complete peak separation for this region. We used Gaussian
resolution enhancement to analyze these resonances in detail.
Since e⁄cient Gaussian apodization is accompanied by a de-
crease in S/N we used v10-fold concentrated CSF to carry
out these experiments. This sample concentration resulted in
slight NH shifts for some signals when compared with samples
prepared according to our routine protocol (only 3-fold con-
centration, owing to the limited availability of CSF from each
individual patient). However, these minor chemical shift dif-
ferences proved to be irrelevant for signal assignments.
Fig. 1 displays the high-¢eld parts of 1-D and 2-D 1H
NMR spectra of a typical highly concentrated CSF sample.
The methyl region within 0.9456 NH6 0.975 ppm clearly com-
prises the two leucine doublets and the low-¢eld peak of the
isoleucine triplet, but also the low-¢eld K-hydroxyisovalerate
(AHIV) doublet and the high-¢eld peak of the K-aminobuty-
rate (AAB) triplet. The two lower spectra in Fig. 1 demon-
strate that these AHIV and AAB resonances may simply be
hidden in the ‘Leu/Ile’ region of conventional 1-D 1H NMR
spectra, in particular when resolution enhancement proce-
dures cannot be applied because of the low S/N typical of
routine CSF spectra obtained for samples from individual
patients. Our results suggest that the so-called Leu/Ile region
should be more adequately named Leu/AHIV/Ile/AAB. How-
ever, only 25% of the Ile and AAB methyl triplet intensities lie
within this region. Our experience with numerous CSF sam-
ples of patients showed that in most cases, only one integral
value can be obtained for the signal area between 0.94 and
0.97 ppm, representing the sum of the signal areas in question.
Thus, correct quantitation is considerably complicated for
these metabolites. Fig. 1 (bottom spectrum) further demon-
strates that the high-¢eld peak of the Ile triplet overlaps with
the low-¢eld peak of the K-hydroxybutyrate (AHB) triplet,
leaving the central Ile triplet peak as the only signal of this
multiplet that can be used for individual quantitation of iso-
leucine. Moreover, the two low-¢eld peaks of the AAB triplet
are completely superimposed with the high-¢eld valine (Val)
doublet. This situation renders AAB entirely invisible in 1-D
1H NMR spectra since the CH and CH2 protons of AAB give
signal heights below the detection threshold.
3.1.2. Signal separation by changing experimental condi-
tions. It might be argued that changing sample temperature
and/or pH will separate peaks overlapping at 20‡C and pH
7.0, and, consequently, will improve signal assignment and
quantitation. However, in our experience alterations in these
parameters cause increased signal overlap in other spectral
regions so that it will be virtually impossible to de¢ne temper-
ature and pH conditions optimized for all signals. Running
several spectra at two or three di¡erent temperatures and/or
pH values for each patient sample would result in prohibi-
tively long sample preparation, data acquisition and process-
ing times in clinical routine analysis. In addition, repeated
CSF manipulation over several hours enhances the risk of
sample degradation and contamination, resulting in metabo-
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lite loss and increased quantitation errors. In contrast, the use
of ultra-high-¢eld spectrometers will improve resolution for
some resonances in the critical region between 0.90 and 1.05
ppm, as demonstrated by simulated spectra (Fig. 2). At
B0 = 14.1 T (600 MHz, Fig. 2C) the high-¢eld peak of the
Ile triplet is isolated from the low-¢eld peak of the AHB
triplet, and the Ile doublet does no longer overlap with the
high-¢eld Val doublet. At B0 = 18.8 T (800 MHz, Fig. 2D) the
Ile triplet is in e¡ect completely separated from the Leu/AHIV
region between 0.947 and 0.975 ppm. 600 MHz spectra barely
improve the detectability of AAB compared to 400 MHz spec-
tra, while at 800 MHz the central and low-¢eld peaks of the
AAB triplet may be detected, but nevertheless are di⁄cult to
quantitate due to the intrinsically low AAB concentration in
CSF. The two Leu doublets are almost completely separated
at 800 MHz while they still overlap with the low-¢eld AHIV
doublet. As a result, the use of ultra-high-¢eld spectrometers
may signi¢cantly improve detection and quantitation of Ile
methyl signals, while permitting AAB detection without re-
moving serious peak overlap for the AAB methyl triplet.
The low-¢eld AHIV methyl doublet is best isolated from
neighboring signals at 600 MHz while it overlaps more se-
verely at 400 and 800 MHz.
3.1.3. Additional methyl signals: con¢rmation by 2-D
NMR. Several methyl resonances lying between 1.1 and 1.5
ppm, and not yet identi¢ed in our previous publication [12],
were assigned as follows. The doublet at 1.13 ppm, formerly
designated XS1.12 and XS1.14 [12], was found to represent K-
oxoisovalerate (AOIV). This compound has been previously
identi¢ed in CSF by a GC-MS method [21], and by 1-D 1H
NMR spectroscopy of CSF samples measured at pH 2.5 (1.13
ppm) [11]. AOIV is involved in the synthesis of branched-
chain amino acids [22], and was also detected in blood plasma
(1.13 ppm, pH 2.5 [10]), urine (1.12 ppm, pH 2.5 [2]) and
amniotic £uid (1.12 ppm, pH 9.8 [9]). All of these 1H NMR
experiments except one [9] were carried out using lyophilized
samples reconstituted in D2O. Our assignments were con-
¢rmed by JRES and COSY spectra (not shown). The corre-
lation signal detected at 1.13/3.05 ppm is consistent with the
chemical shift of the CH resonance for the authentic com-
pound (value obtained from our data base). Interestingly,
we determined a slightly decreased AOIV chemical shift for
pH 2.5 (1.11 ppm, con¢rmed by a reference solution in D2O)
than the authors cited above, possibly due to the use of v10-
fold concentrated CSF.
The singlet found at 1.27 ppm (previously named XS1.27
[12]) was ascribed to L-hydroxyisovalerate (BHIV). Direct as-
signment of this signal is rather di⁄cult due to the absence of
correlation signals in COSY spectra. Since BHIV is not com-
mercially available as a model compound, Wevers et al. based
their BHIV assignment (singlet at 1.33 ppm, pH 2.5) on GC-
MS studies, and on chemical and biochemical considerations
[11]. We veri¢ed that the singlet observed at 1.27 ppm for pH
7.0 was shifted to 1.33 ppm when the CSF concentrate was
gradually acidi¢ed to pH 2.5 (Fig. 3). The BHIV methylene
singlet (2.55 ppm, pH 2.5 [11]) could not be identi¢ed unam-
biguously in our spectra since in the spectral region at ca. 2.55
ppm, several overlapping signals revealing similar signal areas
were detected, each one being on the order of ca. one third of
the BHIV methyl peak area (see also Section 3.2).
The alanine methyl region of CSF spectra frequently con-
tains four or ¢ve overlapping peaks. For correct alanine (Ala)
quantitation it is essential to avoid contamination of the Ala
doublet by adjacent signals which may be of the same order of
magnitude as the Ala signal itself. The doublet found slightly
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Fig. 1. High-¢eld regions of 1-D and 2-D 1H NMR spectra ob-
tained from a typical concentrated CSF sample. From bottom to
top: high-resolution 1-D spectrum processed with Gaussian resolu-
tion enhancement, skyline f2 projection of a JRES spectrum, JRES
spectrum, COSY-90 spectrum. The broken line connects the AAB
methyl signals. For abbreviations see text.
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down¢eld from alanine is a lactate (Lac) 13C satellite ; the
corresponding high-¢eld satellite was also detected, with
J1H13C = 127.8 Hz and a slight up¢eld isotope shift of 0.006
ppm. In human CSF, lactate may be as much as 100 times
more concentrated than alanine [12]. Thus, despite low natu-
ral 13C abundance (ca. 1%) the low-¢eld Lac satellite may
result in an overestimation of Ala by s 50% unless corrected
for [11]. The ¢fth peak ‘X’ occasionally detected in the Ala
region is as yet unassigned.
Resonances formerly marked XS1.14 and XS1.15 [12] were
assigned to the 1,2-propanediol (1,2pd) methyl doublet, char-
acterized by a chemical shift of 1.15 ppm and a coupling
constant of 6.4 Hz. In COSY spectra, a characteristic corre-
lation peak was detected at 1.15/3.9 ppm. Wevers et al. [11]
have identi¢ed 1,2pd in 1H NMR spectra of patients’ CSF at
pH 2.5 (1.13 ppm, consistent with our results ; see Fig. 3), but
1,2pd was not detected in CSF of untreated healthy or dis-
eased sheep [23]. 1,2pd is a common drug excipient, but may
also be involved in glycerol metabolism [22]. Previously, we
have demonstrated the presence in CSF of another alcohol,
2,3-butanediol (coupling constant 6.2 Hz), exhibiting the same
methyl proton chemical shift as 1,2pd [24]. We were able to
separate these two alcohol methyl resonances in COSY spec-
tra while JRES spectra revealed only one methyl doublet due
to similar coupling constants [24]. However, the presence in
CSF of 2,3-butanediol could be con¢rmed for one patient’s
CSF sample only, whereas 1,2-propanediol was present in
most human CSF samples.
The doublet at 1.07 ppm (previously labeled XS1.06 and
XS1.08 [12]) remains unassigned (‘U’). A minor contribution
to this signal may stem from isobutyrate (a usually unre-
solved, weak doublet slightly up¢eld from the main compo-
nent). Isobutyrate has been detected in human blood plasma
by using ultra-high-¢eld 1H NMR spectroscopy [7], but the
presence of its methyl correlation peak in our COSY spectrum
remains uncertain since we only found intensities very close to
the noise level for 1.07/2.4 ppm. In contrast, correlation with a
multiplet at 2.5 ppm was regularly observed. The pH depend-
ence of the unassigned doublet ‘U’ very much resembles that
of hydroxy acids such as L-hydroxyisovalerate and lactate
(Fig. 3). Therefore, ‘U’ may represent a hydroxy acid that is
not commercially available as an authentic compound. It
should be noted that for pH9 5.0 the methyl resonances of
AOIV, 1.2-propanediol and the unknown compound ‘U’ over-
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Fig. 2. High-¢eld regions of experimental and simulated high-resolution 1H NMR spectra. A: Experimental 400 MHz spectrum of a concen-
trated CSF sample. Neither ¢lter functions nor resolution enhancement were applied during data processing. B: Simulated 400 MHz spectrum
based on Lorentzian line shapes. Comparison between spectra A and B shows that the experimental spectrum does not exhibit pure Lorentzian
line shapes, since most of the signals appear to be broadened at their tops but narrowed near the baseline when compared with the simulated
spectrum. C: Simulated 600 MHz spectrum. D: Simulated 800 MHz spectrum.
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lap signi¢cantly so that the precision of chemical shift deter-
mination is compromised.
3.2. Assignment of additional proton signals
Nicotinate and its derivatives are substrates contained in a
variety of drugs. Nicotinamide (vitamin PP) plays an impor-
tant role in the oxidative pathway of cells where it is con-
verted into NAD and NADP. Nicotinamide was detected in
the CSF of a patient treated with Nicobion, a drug containing
niacinamide (= nicotinamide) as the only active substrate (Fig.
4A, upper spectrum). It exhibits a spectral pattern character-
istic of hetero-aromatic compounds; proton couplings were
identi¢ed by selective homonuclear irradiation. One singlet
at 8.93 ppm (a), two doublets at 8.72 and 8.26 ppm (b and
c) and one triplet at 7.6 ppm (d) were detected. Closer inspec-
tion of the signals revealed the existence of long-range cou-
pling. The singlet was assigned to H2, the doublets to H4 and
H6, and the triplet to H5 of nicotinamide. Control spectra for
Nicobion, nicotinamide and nicotinate solutions in D2O were
run to con¢rm the presence of nicotinamide in CSF. Since
nicotinamide is prescribed to prevent or treat alcoholic ence-
phalopathies related to vitamin PP de¢ciency, there is an in-
creased chance of detecting this molecule in CSF of alcoholic
patients undergoing vitamin treatment.
Particularly increased 2.50 ppm signal heights were ob-
served for CSF samples from two neurological patients. Clos-
er inspection revealed that in these spectra, the most high-¢eld
citrate peak and the low-¢eld part of the glutamine Q-CH2
multiplet (b) were also increased in comparison with ‘normal’
spectra, as well as at least three peaks of the glutamine L-CH2
multiplet (c) (Fig. 4B). Furthermore, a relatively strong addi-
tional singlet was found at ca. 4.04 ppm (a). Both patients had
been given a drug (Nootropyl) containing piracetam (2-oxo-1-
pyrrolidineacetamide) before lumbar puncture. A control
spectrum for a piracetam solution in D2O was acquired to
con¢rm the presence of this compound in the CSF of the
two patients. For this control spectrum, a singlet at 4.02
ppm (a), two triplets at 3.52 and 2.50 ppm (b), and a quintet
at 2.11 ppm were assigned to piracetam protons (control spec-
trum not shown). The same signals were identi¢ed in the CSF
samples in question, with the triplet at 3.52 ppm being ob-
scured by intense glucose signals (Fig. 4B, upper spectrum).
The singlet was assigned to the CH2 protons of the acetamide
moiety, the triplets to the 3-CH2 and 5-CH2 protons, and the
quintet to the 4-CH2 protons. Piracetam is usually prescribed
in myoclonic encephalopathies, or to demented patients. Con-
sequently, these patients should be checked for drug treatment
before CSF analysis.
Pyroglutamate (5-oxo-2-pyrrolidinecarboxylate), a product
formed by spontaneous intramolecular glutamine cyclization
in glutamine solutions not kept deep-frozen, may also reveal a
multiplet at 2.51 ppm (pH 7^8 [25]), and may thus add to the
signal observed at 2.50 ppm. Further pyroglutamate multi-
plets have been reported for 4.18, 2.03 and 2.40 ppm [25].
However, we should have only trace amounts of pyrogluta-
mate in our CSF samples since the sample preparation pro-
tocol employed ensures that no more than 2^3 h elapse be-
tween lumbar puncture and MRS analysis or sample freezing.
During most of this time, samples were kept at 94‡C to avoid
signi¢cant metabolite degradation. Furthermore, as pointed
out in Section 3.1, the unassigned methyl doublet ‘U’ at
1.07 ppm is correlated with a multiplet centered about ca.
2.50 ppm. This multiplet will also contribute to the 2.50
ppm peak. Finally, BHIV which exhibits a CH2 singlet at
2.55 ppm for pH 2.5 [11] will reveal a slightly shifted CH2
signal when measured at pH 7.0. Since we were not able to
determine the exact position of the BHIV CH2 peak we can-
not exclude that it may add to the 2.50 ppm resonance as well.
However, multivariate analysis did not reveal signi¢cant cor-
relation between the signal intensities of the BHIV singlet at
1.27 ppm and the peak observed at 2.50 ppm.
3.3. Assignment con¢rmation by HPLC
AAB could be unambiguously assigned by HPLC. Both
retention time (33.2 min) and UV spectrum of the AAB
peak were taken as a basis for peak identi¢cation; no signi¢-
cant overlap of AAB with adjacent peaks was observed. A
characteristic retention time of 3.6 min was found for the
peak identi¢ed as AOIV, which signi¢cantly overlapped with
a considerably larger pyruvate signal. Therefore, meaningful
UV spectra could not be obtained for AOIV. However, the
order of magnitude of the AOIV signal intensity in compar-
ison with that of other identi¢ed acids in the same chromato-
gram was consistent with relative AOIV concentrations as
obtained by 1H NMR spectroscopy.
4. Conclusion
Several substituted short-chain fatty acids, one alcohol and
two drugs used in neurological treatment were identi¢ed in 1H
NMR spectra of human cerebrospinal £uid by using one- and
two-dimensional NMR methods. This work completes pre-
vious CSF studies by making more metabolites available to
quantitative analysis, thus enhancing the diagnostic potential
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Fig. 3. Chemical shifts of methyl proton signals as a function of pH
for several compounds contained in a concentrated CSF sample.
The unassigned resonance ‘U’ shows the same qualitative behavior
as the hydroxyacid resonances Lac and BHIV, in contrast to the
signals obtained for the alcohol, 1,2pd, and the oxoacid, AOIV.
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of CSF tests. Since the concentrations of the compounds as-
signed in this work have been found to vary signi¢cantly
between CSF samples taken from di¡erent neurological pa-
tient groups, these variations may now be used to establish
more speci¢c hypotheses on the nature of metabolic changes
occurring in neurological diseases, in particular perturbations
of amino acid synthesis. The fact that measurable amounts of
speci¢c drugs can be detected in some patients’ CSF may be
exploited for pharmacokinetic studies of molecules crossing
the blood brain barrier.
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